At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Gemcitabine, and 2 other interventions for Lung Cancer. Completed, enrolled 110 participants across 18 sites.
Detailed Summary
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.
Study Details
Timeline
Interventions
pemetrexed 500 mg/m2
gemcitabine 1500 mg/m2
bevacizumab 10mg/kg bevacizumab 15mg/kg
carboplatin AUC=5